全文获取类型
收费全文 | 35906篇 |
免费 | 2880篇 |
国内免费 | 984篇 |
专业分类
耳鼻咽喉 | 104篇 |
儿科学 | 958篇 |
妇产科学 | 282篇 |
基础医学 | 2861篇 |
口腔科学 | 111篇 |
临床医学 | 2991篇 |
内科学 | 21561篇 |
皮肤病学 | 144篇 |
神经病学 | 907篇 |
特种医学 | 892篇 |
外国民族医学 | 1篇 |
外科学 | 2988篇 |
综合类 | 458篇 |
现状与发展 | 4篇 |
预防医学 | 1237篇 |
眼科学 | 49篇 |
药学 | 2008篇 |
中国医学 | 99篇 |
肿瘤学 | 2115篇 |
出版年
2024年 | 38篇 |
2023年 | 1647篇 |
2022年 | 2159篇 |
2021年 | 2776篇 |
2020年 | 2207篇 |
2019年 | 1648篇 |
2018年 | 1971篇 |
2017年 | 1697篇 |
2016年 | 1720篇 |
2015年 | 1564篇 |
2014年 | 2980篇 |
2013年 | 2377篇 |
2012年 | 2013篇 |
2011年 | 1977篇 |
2010年 | 1841篇 |
2009年 | 1642篇 |
2008年 | 1314篇 |
2007年 | 1362篇 |
2006年 | 1245篇 |
2005年 | 983篇 |
2004年 | 794篇 |
2003年 | 671篇 |
2002年 | 606篇 |
2001年 | 496篇 |
2000年 | 381篇 |
1999年 | 330篇 |
1998年 | 259篇 |
1997年 | 148篇 |
1996年 | 191篇 |
1995年 | 155篇 |
1994年 | 95篇 |
1993年 | 78篇 |
1992年 | 54篇 |
1991年 | 66篇 |
1990年 | 71篇 |
1989年 | 60篇 |
1988年 | 38篇 |
1987年 | 18篇 |
1986年 | 14篇 |
1985年 | 19篇 |
1984年 | 13篇 |
1983年 | 10篇 |
1982年 | 5篇 |
1981年 | 10篇 |
1980年 | 3篇 |
1979年 | 7篇 |
1976年 | 5篇 |
1974年 | 3篇 |
1973年 | 2篇 |
1972年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
Saleh A Alqahtani Massimo G Colombo 《World journal of gastrointestinal oncology》2021,13(12):2038-2049
Globally, hepatocellular carcinoma (HCC) is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates. Unfortunately, many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate. Before 2008, no effective drug treatments existed to prolong survival, until the breakthrough multi-tyrosine kinase inhibitor (TKI) sorafenib was developed. It remained the standard treatment option for advanced HCC for 10 years, with a battery of other candidate drugs in clinical trials failing to produce similar efficacy results. In 2018, the REFLECT trial introduced another multi-TKI, lenvatinib, which has non-inferior overall survival compared with sorafenib. Thus, offering patients and their treating physicians two effective treatment options. Recently, immunotherapy-based drugs, such as atezolizumab and bevacizumab, have shown promising results in patients with unresectable HCC. This review summarizes clinical trial and real-world data studies of sorafenib and lenvatinib in patients with unresectable HCC. We offer guidance on the optimal choice between the two treatments and discuss the potential of immunotherapy-based combination; when more data become available, this will likely make the choice between sorafenib and lenvatinib somewhat obsolete. 相似文献
55.
56.
57.
58.
59.
《Journal of pediatric surgery》2023,58(9):1715-1726
ObjectiveTo compare the outcomes of patients with multifocal hepatoblastoma (HB) treated at our institution with either orthotopic liver transplant (OLTx) or hepatic resection to determine outcomes and risk factors for recurrence.BackgroundMultifocality in HB has been shown to be a significant prognostic factor for recurrence and worse outcome. The surgical management of this type of disease is complex and primarily involves OLTx to avoid leaving behind microscopic foci of disease in the remnant liver.MethodsWe performed a retrospective chart review on all patients <18 years of age with multifocal HB treated at our institution between 2000 and 2021. Patient demographics, operative procedure, post-operative course, pathological data, laboratory values, short- and long-term outcomes were analyzed.ResultsA total of 41 patients were identified as having complete radiologic and pathologic inclusion criteria. Twenty-three (56.1%) underwent OLTx and 18 (43.9%) underwent partial hepatectomy. Median length of follow-up across all patients was 3.1 years (IQR 1.1–6.6 years). Cohorts were similar in rates of PRETEXT designation status identified on standardized imaging re-review (p = .22). Three-year overall survival (OS) estimate was 76.8% (95% CI: 60.0%–87.3%). There was no difference in rates of recurrence or overall survival in patients who underwent either resection or OLTx (p = .54 and p = .92 respectively). Older patients (>72 months), patients with a positive porta hepatis margin, and patients with associated tumor thrombus experienced worse recurrence rates and survival. Histopathology demonstrating pleomorphic features independently associated with worse rates of recurrence.ConclusionsThrough proper patient selection, multifocal HB was adequately treated with either partial hepatectomy or OLTx with comparable outcome results. HB with pleomorphic features, increased patient age at diagnosis, involved porta hepatis margin on pathology, and the presence of associated tumor thrombus may be associated with worse outcomes regardless of the local control surgery offered.Level of EvidenceIII. 相似文献
60.